Pediatric Gastroenterology, Hepatology & Nutrition

  • 제19권3호
  • /
  • Pages.175-185
  • /
  • 2016
  • /
  • 2234-8646(pISSN)
  • /
  • 2234-8840(eISSN)
대한소아소화기영양학회 (The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition)
권호 표지
DOI QR코드

DOI QR Code

Henoch-Schonlein Purpura in Children Hospitalized at a Tertiary Hospital during 2004-2015 in Korea: Epidemiology and Clinical Management

  • Lee, Yong Hee (Department of Pediatrics, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Kim, Yu Bin (Department of Pediatrics, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Koo, Ja Wook (Department of Pediatrics, Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Chung, Ju-Young (Department of Pediatrics, Sanggye Paik Hospital, Inje University College of Medicine)
  • 투고 : 2016.06.09
  • 심사 : 2016.07.12
  • 발행 : 2016.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To investigate the epidemiology, clinical manifestations, investigations and management, and prognosis of patients with Henoch-Schonlein purpura (HSP). Methods: We performed a retrospective review of 212 HSP patients under the age of 18 years who were admitted to Inje University Sanggye Paik Hospital between 2004 and 2015. Results: The mean age of the HSP patients was 6.93 years, and the ratio of boys to girls was 1.23:1. HSP occurred most frequently in the winter (33.0%) and least frequently in the summer (11.3%). Palpable purpura spots were found in 208 patients (98.1%), and gastrointestinal (GI) and joint symptoms were observed in 159 (75.0%) and 148 (69.8%) patients, respectively. There were 57 patients (26.9%) with renal involvement and 10 patients (4.7%) with nephrotic syndrome. The incidence of renal involvement and nephrotic syndrome was significantly higher in patients with severe GI symptoms and in those over 7 years old. The majority of patients (88.7%) were treated with steroids. There was no significant difference in the incidence of renal involvement or nephrotic syndrome among patients receiving different doses of steroids. Conclusion: In this study, the epidemiologic features of HSP in children were similar to those described in previous studies, but GI and joint symptoms manifested more frequently. It is essential to carefully monitor renal involvement and progression to chronic renal disease in patients ${\geq}7$ years old and in patients affected by severe GI symptoms. It can be assumed that there is no direct association between early doses of steroids and prognosis.

키워드

참고문헌

  1. Saulsbury FT. Henoch-Schonlein purpura. Curr Opin Rheumatol 2001;13:35-40. https://doi.org/10.1097/00002281-200101000-00006
  2. Rostoker G. Schonlein-Henoch purpura in children and adults: diagnosis, pathophysiology and management. Bio Drugs 2001;15:99-138.
  3. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein purpura [ISRCTN85109383]. BMC Med 2004;2:7. https://doi.org/10.1186/1741-7015-2-7
  4. Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in henoch-schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006;149:241-7. https://doi.org/10.1016/j.jpeds.2006.03.024
  5. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics 2007;120:1079-87. https://doi.org/10.1542/peds.2007-0667
  6. Calvo-Rio V, Loricera J, Mata C, Martin L, Ortiz-Sanjuan F, Alvarez L, et al. Henoch-Schonlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center. Medicine (Baltimore) 2014;93:106-13. https://doi.org/10.1097/MD.0000000000000019
  7. Lu S, Liu D, Xiao J, Yuan W, Wang X, Zhang X, et al. Comparison between adults and children with Henoch-Schonlein purpura nephritis. Pediatr Nephrol 2015;30:791-6. https://doi.org/10.1007/s00467-014-3016-z
  8. Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. Scand J Rheumatol 2006;35:56-60. https://doi.org/10.1080/03009740510026841
  9. Hong JH, Na HJ, Namgung MG, Choe SO, Han BG, Jeong SH, et al. Different clinical courses of Henoch-Schonlein purpura in children, adolescents and adults. Korean J Pediatr 2005;48:1244-51.
  10. Cohen N, Mimouni FB, Friedel N, Amarilyo G. Predictors of hospital length of stay in pediatric Henoch-Schonlein purpura. Rheumatol Int 2015;35:1561-4. https://doi.org/10.1007/s00296-015-3257-6
  11. Oh JM, Park JH. Clinical features of Henoch-Schonlein purpura gastroenteropathy without purpura before diagnosis. Korean J Pediatr Gastroenterol Nutr 2004;7:54-60.
  12. Yang HR, Choi WJ, Ko JS, Seo JK. Intravenous immunoglobulin for severe gastrointestinal manifestation of Henoch-Schonlein purpura refractory to corticosteroid therapy. Korean J Pediatr 2006;49:784-9. https://doi.org/10.3345/kjp.2006.49.7.784
  13. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol 2011;26:2159-66. https://doi.org/10.1007/s00467-011-1919-5
  14. Kawasaki Y, Suzuki J, Murai M, Takahashi A, Isome M, Nozawa R, et al. Plasmapheresis therapy for rapidly progressive Henoch-Schonlein nephritis. Pediatr Nephrol 2004;19:920-3.
  15. Park JM, Won SC, Shin JI, Yim H, Pai KS. Cyclosporin A therapy for Henoch-Schonlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 2011;26:411-7. https://doi.org/10.1007/s00467-010-1723-7
  16. Cherqaoui B, Chausset A, Stephan JL, Merlin E. Intravenous immunoglobulins for severe gastrointestinal involvement in pediatric Henoch-Schonlein purpura: a French retrospective study. Arch Pediatr 2016;23:584-90. https://doi.org/10.1016/j.arcped.2016.03.018
  17. Basaran O, Cakar N, Uncu N, Celikel BA, Kara A, Cayci FS, et al. Plasma exchange therapy for severe gastrointestinal involvement of Henoch Schonlein purpura in children. Clin Exp Rheumatol 2015;33:S-176-80.
  18. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The american college of rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33:1114-21.
  19. Saulsbury FT. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999;78:395-409. https://doi.org/10.1097/00005792-199911000-00005
  20. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Arch Dis Child 2010;95:871-6. https://doi.org/10.1136/adc.2009.167874
  21. Weiss PF, Klink AJ, Localio R, Hall M, Hexem K, Burnham JM, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schonlein purpura. Pediatrics 2010;126:674-81. https://doi.org/10.1542/peds.2009-3348
  22. Masarweh K, Horovitz Y, Avital A, Spiegel R. Establishing hospital admission criteria of pediatric Henoch-Schonlein purpura. Rheumatol Int 2014;34:1497-503. https://doi.org/10.1007/s00296-014-2971-9
  23. Choi SM, Lee KY. Clinico-epidemiologic study of Henoch-Schonlein purpura in children, 1987 through 2003. Korean J Pediatr 2005;48:174-77.
  24. Zhao YL, Liu ZJ, Bai XM, Wang YC, Li GH, Yan XY. Obesity increases the risk of renal involvement in children with Henoch-Schonlein purpura. Eur J Pediatr 2015;174:1357-63. https://doi.org/10.1007/s00431-015-2547-z
  25. Anil M, Aksu N, Kara OD, Bal A, Anil AB, Yavascan O, et al. Henoch-Schonlein purpura in children from western Turkey: a retrospective analysis of 430 cases. Turk J Pediatr 2009;51:429-36.
  26. Kang Y, Park JS, Ha YJ, Kang MI, Park HJ, Lee SW, et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schonlein purpura. J Korean Med Sci 2014;29:198-203. https://doi.org/10.3346/jkms.2014.29.2.198
  27. Hong J, Yang HR. Laboratory markers indicating gastrointestinal involvement of Henoch-Schonlein purpura in children. Pediatr Gastroenterol Hepatol Nutr 2015;18:39-47. https://doi.org/10.5223/pghn.2015.18.1.39
  28. Nagamori T, Oka H, Koyano S, Takahashi H, Oki J, Sato Y, et al. Construction of a scoring system for predicting the risk of severe gastrointestinal involvement in Henoch-Schonlein purpura. Springerplus 2014;3:171. https://doi.org/10.1186/2193-1801-3-171
  29. Sano H, Izumida M, Shimizu H, Ogawa Y. Risk factors of renal involvement and significant proteinuria in Henoch-Schonlein purpura. Eur J Pediatr 2002;161: 196-201. https://doi.org/10.1007/s00431-002-0922-z
  30. Choi HJ, Cho HY, Kim EJ, Lee BS, Kang HG, Ha IS, et al. Prognostic factors in children with Henoch-Schonlein purpura nephritis. J Korean Soc Pediatr Nephrol 2005;9:183-92.
  31. Tabel Y, Inanc FC, Dogan DG, Elmas AT. Clinical features of children with Henoch-Schonlein purpura: risk factors associated with renal involvement. Iran J Kidney Dis 2012;6:269-74.
  32. Wang X, Zhu Y, Gao L, Wei S, Zhen Y, Ma Q. Henoch-Schonlein purpura with joint involvement: analysis of 71 cases. Pediatr Rheumatol Online J 2016;14:20. https://doi.org/10.1186/s12969-016-0080-x
  33. Kim SW, Yoon JW, Jeong SJ. Comparison of the clinical manifestations and prognosis of Henoch-Schonlein purpura in children with and without abdominal pain. Korean J Pediatr Gastroenterol Nutr 2011;14:359-67. https://doi.org/10.5223/kjpgn.2011.14.4.359
  34. Nam EJ, Kim GW, Kang JW, Im CH, Jeon SW, Cho CM, et al. Gastrointestinal bleeding in adult patients with Henoch-Schonlein purpura. Endoscopy 2014;46:981-6. https://doi.org/10.1055/s-0034-1377757
  35. Esaki M, Matsumoto T, Nakamura S, Kawasaki M, Iwai K, Hirakawa K, et al. GI involvement in Henoch-Schonlein purpura. Gastrointest Endosc 2002;56:920-3. https://doi.org/10.1016/S0016-5107(02)70376-3
  36. Park SH, Nam YN, Park SH, Sim SY, Eun BW, Choi DY, et al. Clinical characteristics of childhood Henoch-Schonlein purpura with duodenal involvement by upper gastrointestinal endoscopy. Korean J Pediatr Gastroenterol Nutr 2009;12:156-62.
  37. Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J. Randomised, double-blind, placebo- controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein purpura (HSP). Arch Dis Child 2013;98:756-63. https://doi.org/10.1136/archdischild-2013-303642
  38. Shin JI, Lee SJ, Lee JS, Kim KH. Intravenous dexamethasone followed by oral prednisolone versus oral prednisolone in the treatment of childhood Henoch-Schonlein purpura. Rheumatol Int 2011;31:1429-32. https://doi.org/10.1007/s00296-010-1507-1
  39. Deng F, Lu L, Zhang Q, Hu B, Wang SJ, Huang N. Henoch-Schonlein purpura in childhood: treatment and prognosis. Analysis of 425 cases over a 5-year period. Clin Rheumatol 2010;29:369-74. https://doi.org/10.1007/s10067-009-1329-2
  40. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Outcome of Henoch-Schonlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatr Nephrol 2012;27:933-9. https://doi.org/10.1007/s00467-012-2106-z

피인용 문헌

  1. Late Relapse of Henoch-Schönlein Purpura in an Adolescent Presenting as Severe Gastroduodenitis vol.6, pp.None, 2018, https://doi.org/10.3389/fped.2018.00355
  2. What We Know about Henoch-Schönlein Purpura in Children up to Date? vol.33, pp.25, 2016, https://doi.org/10.3346/jkms.2018.33.e199
  3. Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database vol.16, pp.1, 2018, https://doi.org/10.1186/s12969-018-0247-8
  4. Analysis of seasonal tendencies in pediatric Henoch–Schönlein purpura and comparison with outbreak of infectious diseases vol.97, pp.36, 2018, https://doi.org/10.1097/md.0000000000012217
  5. Recurrent Henoch Schönlein purpura without renal involvement successfully treated with methotrexate vol.64, pp.2, 2019, https://doi.org/10.1177/0036933018809816
  6. Changes of IL-17 and related cytokines in peripheral blood and intestinal mucosa of children with abdominal Henoch-Schonlein purpura vol.27, pp.11, 2016, https://doi.org/10.11569/wcjd.v27.i11.694
  7. Changes in clinical features in Henoch-Schönlein purpura during three decades: an observational study at a single hospital in Korea vol.38, pp.10, 2016, https://doi.org/10.1007/s10067-019-04628-9
  8. Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Schönlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Schönlein vol.19, pp.1, 2019, https://doi.org/10.1186/s12887-019-1802-2
  9. Clinical and Demographic Features of 195 Pediatric Patients with Henoch-Schönlein Purpura, 12-Year Single Center Experience in Shiraz vol.8, pp.4, 2016, https://doi.org/10.5812/pedinfect.99364
  10. Efficacy and safety of Xijiao Dihuang decoction in treating Henoch-Schönlein purpura : Study protocol for systematic review vol.100, pp.51, 2016, https://doi.org/10.1097/md.0000000000028291
  11. Clinical spectrum and outcome of immunoglobulin A vasculitis in children: A 10‐year clinical study vol.75, pp.4, 2016, https://doi.org/10.1111/ijcp.13930
  12. Epidemiological and clinical aspects of immunoglobulin A vasculitis in childhood: a retrospective cohort study vol.47, pp.1, 2021, https://doi.org/10.1186/s13052-021-01182-6